{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-014749","form_type":"8-K","ticker":"DWTX","cik":"0001818844","company_name":"Dogwood Therapeutics, Inc.","filed_at":"2024-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.810973+00:00","generated_at":"2026-05-30T03:46:19.072994+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Dogwood Therapeutics Q3 net loss $2.3M; cash runway depends on $3M Feb 2025 tranche","bullets":["Net loss $2.3M ($2.05/share) vs $1.2M ($1.62) in Q3 2023; R&D and G&A expenses rose.","Cash $2.0M at Sep 30; $16.5M loan from CKLS affiliate received Oct 7; $3M tranche needed Feb 2025 to fund through 2025.","Top-line results from IMC-2 Long-COVID Phase 2a study expected mid-November 2024.","Halneuron Phase 2b CINP interim data expected 2H 2025; FDA fast-track designation granted.","Company formed via combination of Virios and Pharmagesic; pipeline includes IMC-1, IMC-2, and Halneuron."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-014749","json":"https://secwatch.observer/filing/0001558370-24-014749.json","markdown":"https://secwatch.observer/filing/0001558370-24-014749.md","text":"https://secwatch.observer/filing/0001558370-24-014749.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1818844/000155837024014749/0001558370-24-014749-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1818844/000155837024014749/viri-20241107x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T03:46:19.072994+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}